Health · Pharma & Biotech · 18 hrs ago
Roche reports year-long results for eye drug Vamikibart
Roche has presented one-year results for Vamikibart, an experimental treatment for swelling in the center of the retina caused by uveitis, an eye inflammation.
The findings came from two phase 3 studies involving adults with the condition.
Participants received Vamikibart or a sham injection over 52 weeks.
In both studies, a higher share of those given Vamikibart improved their vision than in the comparison groups, and retinal swelling was reduced.
About two-thirds of patients did not need another injection after the initial treatment phase.
Vamikibart is not approved for use.
The US Food and Drug Administration has accepted Roche’s application and plans to decide by July 2027, while applications have also been filed in the European Union, China and Japan.
Roche reported 52-week results showing Vamikibart was associated with sustained vision improvement and reduced retinal swelling.
The results came from two identical Phase III studies, Meerkat and Sandcat, involving adults with uveitis-related macular edema.
In both studies, a higher proportion of patients treated with Vamikibart improved their vision than in the comparison group.
Around two-thirds of patients needed no further injection after the initial treatment phase.
Vamikibart is not approved, and the US Food and Drug Administration plans to decide on Roche’s application by July 2027.
- Who
- Roche reported the results. The studies involved adults with uveitis-related macular edema.
- What
- The 52-week results showed sustained vision improvement and reduced retinal swelling with Vamikibart.
- When
- The results were presented on Saturday. The article was published on October 11, 2026.
- Where
- The results were presented at the American Academy of Ophthalmology’s annual congress in New Orleans.
- Why
- Vamikibart is being studied as a treatment for uveitis-related macular edema.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
Adults in the Meerkat and Sandcat studies received Vamikibart or a sham injection.
Roche presented the results at the American Academy of Ophthalmology’s annual congress in New Orleans.
The US Food and Drug Administration plans to decide on Roche’s Vamikibart application.
- Studies
- Meerkat and Sandcat, two identical Phase III trials
- Treatment period
- 52 weeks
- Patients
- Adults with uveitis-related macular edema
- Further injections
- Around two-thirds of patients needed none after the initial treatment phase
- FDA decision
- Planned by July 2027
- Other applications
- European Union, China and Japan
Sources
Related news
Dong-A launches three ibuprofen-based cold medicines
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Spain withdraws five erectile dysfunction supplements containing undeclared drugs
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental eye drops improve vision in a small study of a rare eye disease
